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Abstract
Background: High-risk HPV DNA testing has been proposed as a primary tool for cervical cancer screening (HPV-
CCS) as an alternative to the Papanicolaou cytology- method. This study describes factors associated with women’s
intentions to attend cervical cancer screening if high-risk HPV DNA testing (HPV-CCS) was implemented as a
primary screening tool, and if screening were conducted every 4 years starting after age 25.
Methods: This online survey was designed using the Theory of Planned Behaviour to assess factors that impact
women’s intentions to attend HPV-CCS among women aged 25–69 upon exit of the HPV FOCAL trial. Univariate
and regression analyses were performed to compare the demographic, sexual history, and smoking characteristics
between women willing and unwilling to screen, and scales for intention to attend HPV-CCS. A qualitative analysis
was performed by compiling and coding the comments section of the survey.
Results: Of the 981 women who completed the survey in full, only 51.4 % responded that they intended to attend
HPV-CCS with a delayed start age and extended screening interval. Women who intended to screen were more
likely to have higher education (AOR 0.59, 95 % CI [0.37, 0.93]), while both positive attitudes (AOR 1.26, 95 % CI
[1.23, 1.30]) and perceived behavior control (AOR 1.06, 95 % CI [1.02, 1.10]) were significant predictors of intention
to screen. Among women who provided comments in the survey, a large number of women expressed fears about
not being checked more than every 4 years, but 12 % stated that these fears may be alleviated by having more
information.
Conclusions: Acceptability of increased screening intervals and starting age could be improved through enhanced
education of benefits. Program planners should consider measures to assess and improve women’s knowledge,
attitudes and beliefs prior to the implementation of new screening programs to avoid unintended consequences.
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Background
Globally, cervical cancer is the fourth most common
type of cancer in women [1]. In high income countries,
implementation of cytology programs for cervical cancer
screening (CCS) have led to significant reductions in cer-
vical cancer incidence and mortality [2]. However, there
are limitations in the screening performance of cytology
including its low sensitivity which means testing must be
repeated every two or 3 years, and high cost of infra-
structure for implementing and maintaining program-
ming quality [3–5]. It is now well established that high-
risk types of human papillomavirus (HR-HPV) are the
cause of cervical cancer [6–8], and the use of HR-HPV
DNA testing as a primary tool for cervical cancer
screening (HPV-CCS) has been recommended [9–14].
As a more sensitive yet less specific test, it is proposed
that HR-HPV DNA testing be used as the first-line test,
with those HPV positive receiving second line triage
tests with higher specificity, such as cytology or HPV
genotyping [11–13, 15–17].
Clinical trials have confirmed increased detection of
pre-cancerous lesions with the use of HR-HPV DNA
testing compared to cytology [18–20]. A recent pooled-
analysis by Ronco et al. found that HPV-CCS provided
60–70 % greater protection against invasive cervical can-
cers compared to cytology [15]. Their findings also dem-
onstrated that the efficacy of HPV-CCS is maximized by
extending the screening interval to every 5 years for
HPV negative women, and with screening beginning
after the age of 30 years [15, 21]. Similarly, an American
study of over 42,000 women concluded that HPV pri-
mary testing with reflex genotyping in women starting at
age 25 years was as effective as a hybrid screening strat-
egy of cytology or co-testing while using fewer screening
tests [17]. While the use of HPV as the primary tool for
CCS may offer improved detection of precancerous le-
sions and invasive cancer, the switch from cytology to
HPV may have unintended consequences on women’s
participation in cervical cancer screening programs due
to changes as a result of the use of HPV testing [22].
HPV is a sexually acquired virus, and its use as a test
may change a ‘blameless’ screen for cancer into one
where patients start to focus on the sexual transmissibil-
ity of HPV [23–25]. It is also uncertain whether women
will accept changes to screening regimens, including de-
layed starting age and extended intervals.
Currently in British Columbia (BC), Canada, screening
begins at age 21, or approximately 3 years after sexual
debut, and screening is recommended every 2 years. In
our previous study, women’s intention to be screened
with HPV decreased from 84.0 to 51.4 % when they were
advised about the delayed start for screening and the ex-
tended interval [22]. In this follow-up analysis we will
explore the demographic and risk factors, as well as
underlying constructs of behavior associated with
women’s intention to be screened for cervical cancer
when the age to start screening is delayed until age 25
and the screening interval is extended to 4 years.
Methods
Objectives
The goal of this study was to determine the factors asso-
ciated with women’s intentions to be screened for cer-
vical cancer if HR-HPV DNA testing was used instead of
Pap smears when screening was conducted every 4 years
and screening started at 25 years of age.
Participants
Survey participants were recruited at study exit from the
HPV FOCAL trial (ISRCTN79347302). HPV FOCAL is
a clinical trial determining the efficacy of HPV based
primary screening to liquid based cytology (LBC) for the
detection of cervical intraepithelial neoplasia grade 2 or
greater (CIN2+). Trial methods are described in detail
elsewhere [26, 27] but briefly, women in BC aged 25–65
eligible for routine cervical cancer screening were re-
cruited through the provincial Cervical Cancer Screen-
ing Program by collaborating family physicians and
randomized to receive either HR-HPV DNA testing or
LBC. Women were provided study information prior to
enrollment, along with the consent form [26]. The infor-
mation package provided to participants included de-
tailed description of Pap screening in BC, HPV and its
association with cervical cancer,, HR-HPV testing, the
study purpose and the differences between the study
arms and the follow-up algorithms in each of these study
arms. Participants and their family physicians were
both initially blinded to study arm allocation since
randomization occurred when samples were received
at the laboratory. Although study allocation was never
expressly stated to participants, there were opportun-
ities throughout the study where women could have
become aware of their study allocation based on dur-
ation of follow up, or information provided by their
family physician.
Participants were invited to complete the survey at
exit if they had completed the study per protocol
[26]. At the time the data was abstracted, primarily
participants in the safety arm were eligible to
complete the survey. Women in the safety arm re-
ceived HR-HPV DNA testing at baseline, and exited
the study 2 years later with LBC testing 2 years later.
Additionally women from the control arm, the safety
arm, and the intervention arm who had been dis-
charged from the study early due to colposcopy find-
ings were also invited to complete the survey.
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Survey design
At study exit, women were invited via email to complete
an electronic survey. Women were provided with back-
ground information on HPV, transmission, and a ration-
ale for the use of primary HR-HPV DNA testing
including an extended screening interval (Appendix 1).
The survey was based on Theory of Planned Behaviour
(TPB) [28], which has been widely used to understand
factors associated with conducting a specific health be-
haviour [29]. It examines the most proximate determin-
ant of the health behaviour, the intention to conduct the
behaviour as well as the key constructs underlying the
behaviour. As part of the TPB, three particular con-
structs are examined: knowledge and attitudes to the
health behaviour, ability to control access to the behav-
iour (perceived behavioural control), and key personal
and institutional influencers in the decision to engage in
the health behaviour (direct and indirect subjective
norms). In addition, we examined the role of partners
regarding HPV test results. Items related to these con-
structs were examined individually, and then combined
into a scale. Survey questions corresponding to each
scale are detailed in Table 1. Item correlation in the scale
is determined using Cronbach’s alpha, and if p < 0.5 then
items within the scale are dropped until acceptable
agreement is achieved. The details of how scale
consistency was achieved for the questions used in this
survey, and scale characteristics are detailed elsewhere
[22]. Participants were provided a space at the end of
the survey to include any comments. Ethics approval for
this study was obtained from the University of British
Columbia Research Ethics Board (H06-04032).
Analysis
Univariate and regression analyses were performed
using SAS (v. 9.3.1) to compare the characteristics of
survey responders to non-responders, in addition to
presenting demographic, sexual history, smoking
data, and scales for intention to attend HPV-CCS.
All variables that reached significance of p ≤ 0.2 were
considered for stepwise logistic regression modeling
[30]. A logistic regression model was created to
Table 1 Characteristics of scale items
Screening concepts Scale items
Attitudes to HPV testing every 4 years and after
age of 25
A22. Having an HPV test to screen for cervical cancer every 4 years





Subjective Norms: Direct SND 2: Most people who are important to me would think that I should have an
HPV test to screen for cervical cancer instead of a Pap smear
SND3: People who are important to me would expect me to have an HPV test
to screen for cervical cancer instead of a Pap smear
SND4. I would feel under social pressure to have an HPV test to screen for
cervical cancer instead of a Pap smear
SND4: I would feel under social pressure to have an HPV test to screen for cervical
cancer instead of a Pap smear
Subjective Norms: Indirect
SNI5. My family physician would think that I should have an HPV test to screen for
cervical cancer instead of a Pap smear
SNI6. What my family physician thinks is important to me
SNI7. My friends would think that I should have an HPV test to screen for cervical
cancer instead of a Pap smear
SNI8. What my friends think is important to me
SNI9. My spouse/partner would think that I should have an HPV test to screen for
cervical cancer instead of a Pap smearSNI10. What my spouse/partner thinks is
important to meSNI11. The BC Cancer Agency would recommend that I should
have an HPV test to screen for cervical cancer instead of a Pap smear
SNI12. What the BC Cancer Agency recommends is important to me
Role of partners CP13. If I had a cervical cancer screening result that showed I had an HPV infection,
I would feel comfortable sharing the results with my partner(s)
CP14. My spouse would be understanding if I had an HPV infection
Perceived behavioral control [22] PBC15. I am confident that I could have an HPV test to screen for cervical cancer
instead of a Pap smear
PBC16. For me to have an HPV test to screen for cervical cancer instead of a Pap smear would be
PBC17. Whether or not I would have an HPV test to screen for cervical cancer instead of a Pap
smear would be entirely up to me
PBC18. How much control would you have over whether you had an HPV test to screen for
cervical cancer instead of a Pap smear?
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determine predictors of women’s intentions to par-
ticipate in a screening program grounded in a new
paradigm with HPV, extended intervals and delayed
start, with odds ratios (OR) and 95 % confidence in-
tervals (CI) to measure the strength and precision of
associations. Responses from the comments section
were compiled and coded and grouped into themes
in NVivo (v 10) by a research assistant who was not
previously involved in survey development, survey ad-
ministration, data collection, data abstraction or ana-
lysis. Themes were independently reviewed and
revised by a senior research staff. Themes that related
to the extended screening interval or delayed age to
start screening were summarized for this study.
Results
In total, 2016 email invites were sent to women who had
exited the HPV FOCAL trial. 1538 received the survey,
1466 unique women clicked onto the survey, and 981
completed the entire survey (Table 2). There were no
demographic or risk behavior differences between survey
respondents and non-respondents [22]. A total of 51.4 %
(504/981) women responded that they intend to partici-
pate in HPV-CCS with a delayed start of age 25 and an
extended screening interval (Table 3).
The results of the univariate analysis are captured in
Table 3. Women with more than high school education
were more likely to intend to attend screening with HPV
with extended interval and delayed start dateagreed they
would attend screening (89.3 % vs 83.4 %, p = 0.007). No
other demographic characteristics (ie. age at recruit-
ment, marital status, number of lifetime sexual partners,
ethnicity, or ever smoked cigarettes) were statistically
significant. All scale items for attitudes, subjective norms
(direct & indirect), and perceived behavior control were sig-
nificantly associated with intention to screen with HPV
with an extended interval and delayed start date (p < 0.001),
while items assessing the impact of partners were not
significant (p = 0.33).
In the final logistic model, women with the intention
to screen at age 25 and every 4 years were more
likely to be educated beyond high school (AOR 0.59,
95 % CI [0.37, 0.93]) (Table 4). Both positive attitudes
regarding the value of HPV testing (AOR 1.26, 95 %
CI [1.23, 1.30]), and perceived behavior control (AOR
1.06, 95 % CI [1.02, 1.10]) were also significant pre-
dictors of intention to screen in this scenario
(Table 4). Direct and indirect subjective norms were
not significant predictors of intention to screen in
this model.
Among 981 women who completed the survey, 316
(32 %) participants provided comments: 14 from the
control arm, 284 from the safety arm and 18 from
the intervention arm. The mean age for these women
is 46. They were predominantly married (67 %), half
of whom were university graduates or had a univer-
sity advanced degree (52.2 %). Twenty-two percent of
all comments were related to the extended screening
interval. While some women stated that the 4-year
interval would be an improvement over screening
every year, a large number of women expressed fears
about not being checked more often than every
4 years. This was especially true of older women who
have historically been told to have a Pap yearly for
most of their lives. As one participant stated, “I worry
that only being tested every 4 years gives plenty of
time for issues to arise and go untreated”. Seven per-
cent of women who commented expressed concerns
over the delayed screening age, for example one par-
ticipant stated “Age (25) is too late. I had a 19 year
old staff member with cervical cancer. Girls have sex
as early as 14…11 years is too long to wait”. Another
stated “How did you come up with the every 4 years
and starting at 25 years old? Should it not be more
frequent at a younger age? It just seems to be an ar-
bitrary number”. Twelve percent of the comments
suggested that their fears about the new HPV testing
technology and the extended interval may be allevi-
ated by having more information.
Discussion
Many countries are considering, or have confirmed im-
plementation of HPV testing as the primary method for
cervical cancer screening including the United States
(U.S.), Australia, and Canada [31–36]. The higher sensi-
tivity and negative predictive value compared to cytology
leads to higher detection of pre-cancerous lesions, and
lower incidence of cervical cancer which is why the
screening interval can be safely extended [15]. In this
study, participants of HPV FOCAL [22, 26, 27]
Table 2 Summary of survey responses collected
Category Count Percentage (%)
Number of invites 2016
Number of clicks on survey (received) 1538 100
Number of unique respondents 1446 94.02
Number of respondents who did not
submit survey as complete
191 12.42
Number of respondents with duplicated
complete surveys
3 0.19
Number of respondents who did not
answer all questions
250 16.25
Number of respondents with eligible results 1094 71.13
Number of unique respondents with eligible
results
1094 71.13
Number of eligible respondents who answered
all short EPI-Q
981 63.78
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completed a survey based on the Theory of Planned Be-
haviour to assess women’s intention to attend HPV-CCS,
which uses scales for attitudes, direct and indirect sub-
jective norms, and perceived behaviour control. The goal
was to assess factors related to intention to attend HPV
testing as the primary method for CCS if screening were
conducted every 4 years and starting at age 25. Although
most women expressed intention to attend HPV-CCS,
willingness decreased substantially when coupled with
the extended screening interval and delayed screening
start (84.2 to 54.2 %, to 51.4 % respectively). Unfavorable
beliefs about extending the screening interval were also
observed in studies in the U.S. among women of meno-
pausal age enrolled in an HPV testing clinical trial [37],
and among low income women [38]. In our study, most
demographic factors were not significant predictors of
willingness to attend screening, while positive predictors
were attitudes regarding the value of HPV testing, per-
ceived behavior control, and higher education.
The lower acceptability of the extended screening
interval could lead to unintended consequences and im-
pacts on screening programs. Women may choose to re-
turn for screening every 2 to 3 years instead of the
recommended 4 to 5 years. This could lead to over-
Table 3 Univariate analysis of demographic factors, risk factors, and scales for intention to attend for HPV-CCS – “I would be willing
to have an HPV test to screen for cervical cancer after the age of 25 and every 4 years instead of a Pap smear every year after becoming
sexually active”
Variable Group Overall Agree Disagree p-valuea
Overall N(%) 981(100 %) 504(51.4 %) 477(48.6 %)
Marital Status Divorced 108(11.0 %) 54(10.7 %) 54(11.3 %) 0.46
Common law/married 689(70.2 %) 363(72.0 %) 326(68.3 %)
Never married 112(11.4 %) 53(10.5 %) 59(12.4 %)
Widowed 7(0.7 %) 5(1.0 %) 2(0.4 %)
Missing 65(6.6 %) 29(5.8 %) 36(7.5 %)
Education High school or less 133(13.6 %) 54(10.7 %) 79(16.6 %) 0.007
More than high school 848(86.4 %) 450(89.3 %) 398(83.4 %)
Sexual Partners - Ever 0 1(0.1 %) 1(0.2 %) 0 0.42
1 185(18.9 %) 96(19.0 %) 89(18.7 %)
2–5 364(37.1 %) 193(38.3 %) 171(35.8 %)
6–10 221(22.5 %) 110(21.8 %) 111(23.3 %)
11–50 198(20.2 %) 101(20.0 %) 97(20.3 %)
>50 12(1.2 %) 3(0.6 %) 9(1.9 %)
Ethnic Origin Chinese 81(8.3 %) 37(7.3 %) 44(9.2 %) 0.47
Aboriginal 24(2.4 %) 11(2.2 %) 13(2.7 %)
Other 876(89.3 %) 456(90.5 %) 420(88.1 %)
Smoke, Ever No 627(63.9 %) 331(65.7 %) 296(62.1 %) 0.24
Yes 354(36.1 %) 173(34.3 %) 181(37.9 %)
Age, Recruitment Median(IQR) 45(38–53) 45(38–54) 44(38–51) 0.07
Attitudes to HPV testing (A1) Mean score (SD) 19.5(7.1) 23.6(5.1) 15.2(6.3) <0.001
Subjective Norms, Direct (SND2-3) Mean score (SD) 11.0(2.6) 11.5(2.5) 10.5(2.6) <0.001
Subjective Norms, Indirect (SNI5-12) Mean score (SD) 34.8(31.9) 42.2(30.2) 27.0(31.9) <0.001
Perceived Behavioural Control (PBC15-18) Mean score (SD) 23.4(4.1) 24.2(3.8) 22.6(4.3) <0.001
Contacting Partners (CP13-14) Mean score (SD) 12.6(2.2) 12.7(2.2) 12.5(2.3) 0.33
a based on either chi-square or Kruskal-Wallis test as appropriate on valid data only
Table 4 Adjusted odds ratio estimatesa for factors associated
with intention to attend for HPV-CCS
Dependent variable Independent variables Adjusted
OR
95 % CI
“I would be willing to
have an HPV test to
screen for cervical
cancer after the age
of 25 and every 4 years





4 years after the





Education 0.59 (0.37, 0.93)
a Stepwise logistic regression was used to select final variables from full
multivariable model (variables with p value ≤0.2 in univariate analysis were
considered for multivariable model)
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screening and potentially over-treatment for cervical le-
sions that could resolve without treatment. In studies
conducted in the U.S., the majority of women surveyed
preferred to screen annually despite knowledge of
changes to guidelines recommending an extended
screening interval [37, 38]. In both studies the physi-
cian’s recommendation was an important influence on
acceptability and patient behavior [37, 38]. These and
other studies have shown that patient expectations or
anxieties influence the screening recommendations of
health care providers, and that this often results in over-
screening in women [37–41]. Some reasons women have
continued annual visits include a desire for routine
checkup, other gynecologic or health concerns, to main-
tain relationships with their physician, and reassurance
of continued health [37]. Other studies in the U.S. have
noted that physicians often provide screening more fre-
quently than new guidelines recommend, either on pa-
tient request, or out of concern that patients would not
attend annual health exams unless cervical cancer
screening was included [37, 39, 42]. Over-screening
would increase probability of a false positive result,
which leads to iatrogenic harm such as anxiety, and
over-treatment. It would also use valuable health care re-
sources unnecessarily. Similarly, if women attend screen-
ing before the recommended age of 25 or 30 years, or
more frequently than recommended, the chances are
higher HPV test with higher sensitivity would detect
transient infections that would otherwise regress on
their own. Programs must anticipate women’s potential
responses and concerns with significant changes such as
these, and should ensure robust planning and education
to mitigate any negative impact on screening attendance
or health service resource utilization.
It has been reported elsewhere that the adverse emo-
tional responses experienced by women are directed at
the HPV infection itself rather than HPV testing [43].
Feelings of stigma, embarrassment and anxiety of having
a sexually transmitted infection could be exacerbated in
the context of an older age to start screening or delayed
screening interval. Efforts to increase patient’s know-
ledge of cervical cancer screening and HPV infection to
dispel myths and misconceptions, normalize HPV, and
improve attitudes are widely recommended by re-
searchers [37, 38, 43]. Our study population is a cohort
of educated women who participated in a clinical trial,
the vast majority of whom received both cytology and
HR-HPV DNA testing for cervical cancer screening, at
different points during trial participation. Overall, the re-
sults of this survey suggest that attitudes and beliefs held
by women would likely influence their willingness to
participate in HPV-CCS in the event that the screening
interval was extended and age of starting screening were
increased. These findings have important programmatic
implications with regard to health information commu-
nication and knowledge translation. Health care pro-
viders will play a pivotal role in communicating to their
patients changes in cervical cancer screening programs.
Providers need to be supportive of changes to programs,
and relay information appropriately to ensure patients
are at ease with a transition to HPV-CCS. Public health
leaders should carefully consider how messages are com-
municated to the public and to practitioners as changes
are implemented to ensure acceptance and uptake.
Limitations
Not all email addresses to which the survey was sent
were functional, and the overall response rate was 63 %,
therefore, selection bias is possible. However, our previ-
ous study [22] demonstrates that respondents and non-
respondents did not differ significantly in demographic
or risk factors, which may indicate that our sample was
representative of the FOCAL study population, which in
itself was representative of the provincial population tar-
geted for cervical cancer screening. The vast majority of
women were from the safety arm, and therefore would
have received both cytology and HPV testing at different
times in the study, however a very small proportion of
the population who were discharged early did not re-
ceive HPV-CCS. Although detailed study information in-
cluding HPV-CCS was provided at the time of
enrollment and consent, it is difficult to determine how
well participants understood this information, or how
much they recalled after 2 years when the survey was
administered. It is also possible that despite having par-
ticipated in HPV-CCS for the study, women still may
not have known specifically what type of testing their
samples received in the study, and may have incorrectly
assumed they were HPV negative or positive, depending
on how their provider conveyed results to them. Know-
ledge of their results may have had an impact on how
they answered questions in the survey. Women partici-
pating in FOCAL were recruited from two main geo-
graphic areas in BC, and therefore, this study may not
be generalizable to all women in BC. It should also be
noted that the women who provided comments may
over represent women who were concerned about
screening and may not be representative of all women
who were eligible to participate in the survey.
Conclusion
As programs begin planning for implementation of HR-
HPV DNA testing as the primary tool for cervical cancer
screening, it becomes important to assess the acceptabil-
ity and willingness of this screening technology among
women currently engaged in screening programs. This
study assessed women’s intention to attend HPV-CCS,
using scales for attitudes, direct and indirect subjective
Ogilvie et al. BMC Public Health  (2016) 16:213 Page 6 of 8
norms, and perceived behaviour control based on the
Theory of Planned Behaviour. All women were provided
information about HPV and HPV testing at when they
consented to participate in HPV FOCAL. Our results
demonstrated that women’s intention to attend HPV-
CCS decreased significantly with the introduction of the
longer screening interval and the delayed starting age for
screening. Attitudes toward HPV-CCS, and perceived
behavior control were particularly important factors in
women’s intention to attend screening. This has import-
ant implications for program planners who are consider-
ing changes to screening programs and want to avoid
unintended consequences such as reducing the uptake
of screening, or over-screening. Our findings also indi-
cate a need for robust and targeted messaging and edu-
cation on HPV and HPV based CCS for women and
healthcare providers.
Availability of data and materials
Data requests can be directed to the corresponding
author.
Appendix
Background information provided prior to study
questionnaire
Thanks for participating in the HPV FOCAL trial. We
invite you to complete this on-line survey in order to
help us to plan for the future of cervical cancer screen-
ing in British Columbia. We are conducting this survey
to help understand women’s attitudes to screening for
cervical cancer with HPV testing instead of pap smears.
This survey will take you about 10 min to complete, and
all who complete the survey are eligible to win one of 5
iPODs. Please remember, your name, or any other per-
sonal identifiers are not linked with the questionnaire re-
sponses in any way.
Here is some background information for you to con-
sider before you complete this survey.
The human papillomavirus (HPV) is a common virus
that can infect the cervix (part of a woman’s womb). It is
now known to be the cause of cervical cancer. Women
develop HPV infections in the cervix after having sexual
activity with a partner who is infected with HPV. How-
ever, HPV is so common that over 75 % of sexually-
active women will have an HPV infection of their cervix
sometime during their life. Most women who find out
they have an HPV infection in the cervix after the age of
30, were infected with HPV years before. Over 90 % of
women who are infected with HPV in the cervix get rid
of the infection naturally. It is only women who have
longstanding infections with certain types of HPV who
may be at risk for developing cervical cancer. Women
may not have known it in the past, but it is these same
HPV infections that are the most common reason for
abnormal Pap smears.
Right now in BC, women start cervical cancer screen-
ing once they become sexually active. We now know
that testing for HPV infections in the cervix is more ac-
curate than the Pap smear for predicting whether or not
a woman will develop cervical cancer, So, in BC, women
would be screened every 4 years with HPV testing in-
stead of every year with Pap screening.
Competing interests
The authors declared that they have no competing interests
Authors’ contributions
Dr. GO had full access to all study data and had final responsibility for the
decision to submit the manuscript for publication. All authors contributed to
study design, data interpretation and generation of conclusions. GO and LS
supervised the data acquisition, GO and FK led the data analysis. GO and HP
prepared the first draft of the manuscript and all authors contributed to
editing and critical analysis of the manuscript and conclusions.
Acknowledgements
The authors would like to acknowledge the funding contribution of the
Canadian Institutes of Health Research (CIHR) and the Canadian Foundation
for Women’s Health for the HPV FOCAL trial.
Financial support
This study was part of the HPV FOCAL trial, which is funded by the Canadian
Institutes of Health Research (CIHR). This analysis was funded by the
Canadian Foundation for Women’s Health.
Author details
1University of British Columbia, Vancouver, BC, Canada. 2Women’s Health
Research Institute, Vancouver, BC, Canada. 3British Columbia Cancer Agency,
Vancouver, BC, Canada. 4British Columbia Centre for Disease Control,
Vancouver, BC, Canada. 5Gillings School of Global Public Health, University of
North Carolina Chapel Hill, Chapel Hill, NC, USA. 6Richard M. Fairbanks School
of Public Health, Indiana University-Purdue University Indianapolis,
Indianapolis, IN, USA. 7McGill University, Montreal, QC, Canada. 8BC Women’s
Hospital and Health Centre, Room H203G, 4500 Oak Street, Vancouver, BC
V6H 3 N1, Canada.
Received: 21 August 2015 Accepted: 12 February 2016
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.
GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide. In: IARC
CancerBase, vol. 11. Lyon, France: International Agency for Research on
Cancer; 2012.
2. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and
mortality from cancer of cervix in England: evaluation based on routinely
collected statistics. BMJ. 1999;318(7188):904–8.
3. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy.
[comment]. Am J Epidemiol. 1995;141(7):680–9.
4. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselbad V, Hickey JD. Accuracy
of the Papanicoloau test in screening for and follow-up of cervical cytologic
abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–9.
5. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. The Expected Impact
of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need
for a Paradigm Change. Arch Med Res. 2009;40(6):478–85.
6. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res. 2002;
89(2):183–90.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et
al. Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. J Pathol. 1999;189(1):12–9.
8. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al.
Epidemiologic classification of human papillomavirus types associated with
cervical cancer. N Engl J Med. 2003;348(6):518–27.
Ogilvie et al. BMC Public Health  (2016) 16:213 Page 7 of 8
9. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S, Schiffman
M, et al. Human papillomavirus and cervical cancer. [Review] [172 refs].
Lancet. 2007;370(9590):890–907.
10. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary
screening of cervical cancer precursors. Cancer Epidemiol Biomark Prev.
2000;9(9):945–51.
11. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al.
Management of women who test positive for high-risk types of human
papillomavirus: the HART study.[see comment]. Lancet. 2003;362(9399):1871–6.
12. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long
term predictive values of cytology and human papillomavirus testing in
cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
13. Franco EL. Chapter 13: Primary screening of cervical cancer with human
papillomavirus tests. J Natl Cancer Inst Monogr. 2003;31:89–96.
14. Franco EL, Ferenczy A, Franco EL, Ferenczy A. Is HPV testing with cytological
triage a more logical approach in cervical cancer screening?[comment].
Lancet Oncol. 2006;7(7):527–9.
15. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al.
Efficacy of HPV-based screening for prevention of invasive cervical cancer:
follow-up of four European randomised controlled trials. Lancet. 2014;
383(9916):524–32.
16. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A,
et al. Human papillomavirus DNA versus Papanicolaou screening tests for
cervical cancer.[see comment]. N Engl J Med. 2007;357(16):1579–88.
17. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary
cervical cancer screening with human papillomavirus: End of study results
from the ATHENA study using HPV as the first-line screening test. Gynecol
Oncol. 2015;136(2):189–97.
18. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del Mistro A, et al.
Efficacy of human papillomavirus testing for the detection of invasive
cervical cancers and cervical intraepithelial neoplasia: a randomised
controlled trial. Lancet Oncol. 2010;11(3):249–57.
19. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila
P, et al. Age-specific evaluation of primary human papillomavirus screening
vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;
101(23):1612–23.
20. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P,
Tarkkanen J, et al. Rate of cervical cancer, severe intraepithelial
neoplasia, and adenocarcinoma in situ in primary HPV DNA screening
with cytology triage: randomised study within organised screening
programme. BMJ. 2010;340:c1804.
21. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. EUROGIN 2008
roadmap on cervical cancer prevention. Int J Cancer. 2009;125(10):2246–55.
22. Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, et
al. Women’s intentions to receive cervical cancer screening with primary
human papillomavirus testing. Int J Cancer. 2013;133(12):2934–43.
23. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J. Attitudes
towards HPV testing: a qualitative study of beliefs among Indian, Pakistani,
African-Caribbean and white British women in the UK. Br J Cancer. 2003;
88(1):42–6.
24. Fernandez ME, McCurdy SA, Arvey SR, Tyson SK, Morales-Campos D, Flores B,
et al. HPV knowledge, attitudes, and cultural beliefs among Hispanic men and
women living on the Texas-Mexico border. Ethn Health. 2009;14(6):607–24.
25. Anhang R, Wright Jr TC, Smock L, Goldie SJ. Women’s desired information
about human papillomavirus. Cancer. 2004;100(2):315–20.
26. Ogilvie GS, vanNiekerk D, Krajden M, Martin RE, Ehlen TG, Ceballos K,
Peacock SJ, Smith LW, Kan L, Cook DA, et al. A randomized controlled trial
of Human Papillomavirus (HPV) testing for cervical cancer screening: trial
design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111.
27. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, et al.
Primary cervical cancer screening with HPV testing compared with liquid-
based cytology: results of round 1 of a randomised controlled trial - the
HPV FOCAL Study. Br J Cancer. 2012;107(12):1917–24.
28. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis. 1991;50:
179–211.
29. Hankins M, French D, Horne R. Statistical Guidelines for Studies of the
Theory of Reasoned Action and the Theory of Planned Behaviour. Psychol
Health. 2000;15:151–61.
30. Hosmer DW, Lemeshow S, Sturdivant RX. Wiley Series in Probability and
Statistics : Applied Logistic Regression (3rd Edition). New York: Wiley; 2013.
31. Murphy J, Kennedy EB, Dunn S, McLachlin M, Fung Kee Fung M, Gzik D, et
al. HPV testing in Primary Cervical Screening: A Systematic Review and
Meta-Analysis. J Obstet Gynaecol Can. 2012;34(5):443–52.
32. Health Council of the Netherlands: Population screening for cervical cancer.
The Hague: Health Council of the Netherlands, 2011 2011, Publication no.
2011/07.
33. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee FM, Gzik D, et al.
Cervical screening: a guideline for clinical practice in Ontario. J Obstet
Gynaecol Can. 2012;34(5):453–8.
34. Moyer VA. Screening for Cervical Cancer: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2012;156(12):880–91.
35. Australian Government Medical Services Advisory Committee: Renewal of
the National Cervical Screening Program. In: MSAC 61st Meeting. Canberra:
Australian Government Department of Health; 2014.
36. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A:
HPV testing with cytology triage for cervical cancer screening in routine
practice. Am J Obstet Gynecol 2014, 210(5):474.e471-474.e477.
37. Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE. Patient
Concerns About Human Papillomavirus Testing and 5-Year Intervals in
Routine Cervical Cancer Screening. Obstet Gynecol. 2015;125(2):317–29.
38. Hawkins N, Benard V, Greek A, Roland K, Manninen D, Saraiya M. Patient
knowledge and beliefs as barriers to extending cervical cancer screening
intervals in Federally Qualified Health Centers. Prev Med. 2013;57(5):641–5.
39. Saraiya M, Berkowitz Z, Yabroff K, Wideroff L, Kobrin S, Benard V. Cervical
cancer screening with both human papillomavirus and papanicolaou
testing vs papanicolaou testing alone: What screening intervals are
physicians recommending? Arch Intern Med. 2010;170(11):977–86.
40. Meissner HI, Tiro JA, Yabroff KR, Haggstrom DA, Coughlin SS. Too Much of a
Good Thing? Physician Practices and Patient Willingness for Less Frequent
Pap Test Screening Intervals. Med Care. 2010;48(3):249–59.
41. Haggerty J, Tudiver F, Brown JB, Herbert C, Ciampi A, Guibert R. Patients’
anxiety and expectations: how they influence family physicians’ decisions to
order cancer screening tests. Can Fam Physician. 2005;51(12):1658–9.
42. Perkins R, Anderson B, Gorin S, Schulkin J. Challenges in cervical cancer
prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med.
2013;45(2):175–81.
43. O’Connor M, Costello L, Murphy J, Prendiville W, Martin CM, O’Leary JJ, et al.
‘I don’t care whether it’s HPV or ABC, I just want to know if I have cancer’.
Factors influencing women’s emotional responses to undergoing human
papillomavirus testing in routine management in cervical screening: a
qualitative study. BJOG. 2014;121(11):1421–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ogilvie et al. BMC Public Health  (2016) 16:213 Page 8 of 8
